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aldosterone at the crossroad between activation
of innate immunity and cardiovascular diseases
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This editorial refers to ‘Aldosterone induces trained immu-
nity: the role of fatty acid synthesis’, by C.D.C.C. van der
Heijden et al., doi: 10.1093/cvr/cvz137.
The activation of the renin–angiotensin–aldosterone system, and the
consequent increase in aldosterone levels promote atherosclerosis in
animal models; similar results are observed after aldosterone infusion in
apoE KOmice.1 These effects are blunted by the inhibition of the mineral
corticoid receptor (MR),1 thus supporting a proatherogenic role for the
aldosterone-MR axis in experimental atherosclerosis. The molecular
mechanisms explaining the inflammatory response associated with
increased aldosterone levels have been so far elusive. The work by van
der Heijden et al.2 sheds light on this topic by showing that aldosterone
promotes the epigenetic reprogramming of monocyte-macrophages,
thus supporting the instauration of immunological memory in innate
immune cells also known as ‘trained immunity’,3 via activation of the MR
receptor (Figure 1). These effects were not mediated by either induction
of glycolysis or oxidative phosphorylation as previously suggested for
other inducers of trained immunity.4 At structural level, while aldoste-
rone treatment did not induce formation of foam cells, it significantly
boosted fatty acids synthesis (FAS) via an epigenetic mechanism enrich-
ing H3 histones trimethylated at lysine 4 (H3K4me3) in the promoters
of FAS genes.2
Trained immunity represents a recent acquisition in the field of
immunological memory and identifies the ability of innate immune cells
to retain ‘memory’ of a previous contact with an antigen (trained cells)
and induce an increased responsiveness upon re-challenge with an insult
similar or unrelated to the first one.3 This process results in enhanced
cytokine production and provides a more effective protection against
re-infection. Epigenetic reprogramming is the key mechanism supporting
the acquisition of trained immunity, with selective changes in histone
methylation and acetylation associated with the acquisition of a trained
phenotype.3,5 Epigenetic reprogramming occurring during trained
immunity is linked to profound changes in intracellular metabolism.
Indeed, it is now established that immune cells, upon activation, adapt
their cellular metabolism to cope with proliferation and/or differentia-
tion.6 These changes affect several metabolic pathways such as glycolysis,
tricarboxylic acid cycle, pentose phosphate pathway, fatty acid oxidation,
fatty acid synthesis, cholesterol metabolism, and amino acid/tryptophan
metabolism.7
Aldosterone activates macrophages towards a proatherogenic and
proinflammatory phenotype, with similarities to the M1 macrophage
phenotype.1 At the molecular level, the activation of the aldosterone-
MR pathway increases ROS production in macrophages, influences
monocyte and macrophage migration, proliferation, and efferocytosis,
and affects macrophage lipid accumulation.1 Further, myeloid-specific
knockout of the MR in low-density lipoprotein (LDL)-receptor KOmice
suppressed atherosclerosis induced by a high-fat diet, and likewise
reduced angiotensin II-induced atherosclerosis in ApoE KO mice, sup-
porting a key role for the aldosterone-MR axis in innate immune cells.8
This picture is reflected also in humans, where patients with primary
hyperaldosteronism (PA) have substantially increased cardiovascular
event rates compared with patients with similar blood pressure levels
due to essential hypertension, and also show an increased carotid artery
intima-media thickness and a higher aortic wall stiffness.1
Trained immunity has already been suggested to associate with induc-
tion of glycolysis, which leads to epigenetic remodeling mediated by the
histone deacetylase sirtuin-1.4 A similar metabolic reprogramming
occurs when monocytes are exposed to oxidized LDLs and is associated
with the induction of trained immunity,9 further highlighting the link be-
tween cardio-metabolic diseases and trained immunity. Other additional
cellular pathways have been linked to the induction of trained immunity,
including glutamine and sterol pathways,3 raising the possibility that
targeting these biochemical ways might contribute to modulate trained
immunity.
Interestingly, the report by van der Heijden et al.2 adds a novel piece
to the puzzle by demonstrating that glycolysis, which is fundamental for
beta-glucan induced trained immunity, is dispensable for aldosterone-
induced epigenetic reprogramming and induction of trained immunity.
These events were instead abolished by FAS inhibition, suggesting a
direct link between FAS and induction of the phenotype. Of note, a
recent report in humans excluded the possibility that drugs targeting
the mevalonate pathway, such as statins, although decrease the risk of
cardiovascular events and improve patient’s lipid profile, can affect the
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..trained immunity phenotype present in monocytes from patients with fa-
milial hypercholesterolaemia.10 This observation raises the question on
the proper strategies to revert in vivo ‘trained immunity’; indeed, statins
target mainly the liver and the latter observation supports the hypothesis
that the chances that the drug could directly target ‘trained immune cells’
are limited.5,6
Interestingly, in humans a trained immune phenotype of circulating
monocytes remains apparent even 3months after vaccination with
BCG.4 Given the short circulating half-life of monocytes of only
1–4 days, it is likely that training already occurs at the level of myeloid
progenitor cells in the bone marrow, as unequivocally demonstrated by
recent reports, at least in mouse models.5 From a translational point
of view, these findings suggest the need to further characterize how
metabolic drugs could be used to manipulate ‘trained’ immune cells.
Moreover, it is possible that in vivo the effects of increased aldosterone
levels could be blunted by other feedback mechanisms, and therefore
the relevance of aldosterone on immune cells proinflammatory
activation might be moderate-to-neutral. This could be easily tested by
investigating whether patients with primary hyperaldosteronism present
a ‘trained’ phenotype in innate immune cells.
In conclusion, van der Heijden et al. show that aldosterone induces
innate immune memory and a persistent proinflammatory macrophage
phenotype leading to cardiovascular consequences. These effects were
mainly mediated by innate immune cells. Further studies are needed to
assess the possible involvement of adaptive immune cells in this process,
including effector and regulatory T cells.
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Figure 1 Aldosterone is produced by adrenal glands and target immune cells via activation of mineralocorticoid receptor, which in monocytes reprog-
rammes cellular metabolism towards increased fatty acid synthesis and lipid metabolism, thus contributing to macrophage trained immunity via H3K4me3
enrichment on several gene promoters. Trainedmacrophages might contribute to the detrimental effect of aldosterone on atherosclerosis and cardiovascu-
lar diseases.
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